# IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

> **NCT02028039** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** IPI-145
- **BEHAVIORAL:** Follow-up Visit/Call

## Key facts

- **NCT ID:** NCT02028039
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2016-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028039, "IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02028039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*